Cytokinetics, Inc. : Cytokinetics to Present at BIO CEO and Investor Conference

     Cytokinetics, Inc. : Cytokinetics to Present at BIO CEO and Investor
                                  Conference

South San  Francisco,  CA.,  February 8,  2013  -  Cytokinetics,  Incorporated 
(Nasdaq: CYTK)  announced  today that  Robert  I. Blum,  President  and  Chief 
Executive Officer, is scheduled to present  a corporate update at the BIO  CEO 
and Investor Conference  on Monday,  February 11,  2013 at  1:30 p.m.  Eastern 
Standard Time in the East Foyer Room of the Waldorf Astoria Hotel in New York,
New York.

Interested parties may access the live  audio webcast of this presentation  by 
visiting the  Investor  Relations  section  of  the  Cytokinetics  website  at 
www.cytokinetics.com. The webcast replay of the presentation will be  archived 
on  the  Presentations   page  within  the   Investor  Relations  section   of 
Cytokinetics' website for two weeks following the completion of the event.

About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment
for diseases and conditions associated with aging, muscle wasting or
neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II
clinical trials program and has been granted orphan drug designation and fast
track status by the U.S. Food and Drug Administration and orphan medicinal
product designation by the European Medicines Agency for the potential
treatment of amyotrophic lateral sclerosis, a debilitating disease of
neuromuscular impairment in which treatment with tirasemtiv produced
potentially clinically relevant pharmacodynamic effects in Phase II trials.
All of these drug candidates have arisen from Cytokinetics' muscle biology
focused research activities and are directed towards the cytoskeleton. The
cytoskeleton is a complex biological infrastructure that plays a fundamental
role within every human cell. Additional information about Cytokinetics can be
obtained at www.cytokinetics.com.



This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.

Contact:
Joanna (Jodi) L. Goldstein
Manager, Marketing & Corporate Communications
(650) 624-300



------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1676746
 
Press spacebar to pause and continue. Press esc to stop.